Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minBearish
5 minConsolidating
Daily trend turns up above $160.81
Key levels
Resistance$146.44
Resistance$135.00
Support$128.00
Support$103.71
Latest news & SEC filings
AnalystWedbush Keeps Buy Rating on Protagonist Therapeutics
AnalystHC Wainwright keeps Buy rating on Protagonist Therapeutics, lifts target to $221
AnalystAnalysts Raise Price Target on Protagonist Therapeutics (PTGX)
All PTGX news →Protagonist Therapeutics is a biopharmaceutical company that discovers and develops peptide-based medicines. Its pipeline spans immunology and inflammation, hematology, and metabolic diseases, with lead candidates for psoriasis, polycythemia vera, and obesity. The company collaborates with Johnson & Johnson and Takeda on late-stage programs. It operates primarily in the United States.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$116.00
SEPT Mid Target
$180.00
SEPT High Target
$221.00
Analyst Consensus
$180.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PTGX.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$161.17
59
Moat Score
NARROW
5/9
Piotroski Score
93.4
Altman Z-Score
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| PATEL DINESH V PH D | director officer | Buy | 7,278 | $157K | Sep 10, 2026 |
| PATEL DINESH V PH D | director officer | Sale | 7,278 | $1.0M | Sep 10, 2026 |
| PATEL DINESH V PH D | director officer | Buy | 63,548 | $1.4M | Sep 9, 2026 |
| PATEL DINESH V PH D | director officer | Sale | 63,548 | $9.3M | Sep 9, 2026 |
| PATEL DINESH V PH D | director officer | Buy | 54,174 | $1.2M | Sep 8, 2026 |
| PATEL DINESH V PH D | director officer | Sale | 54,174 | $7.9M | Sep 8, 2026 |
| PATEL DINESH V PH D | director officer | Sale | 510 | - | Sep 3, 2026 |
| PATEL DINESH V PH D | director officer | Buy | 34,239 | $739K | Aug 11, 2026 |
| PATEL DINESH V PH D | director officer | Sale | 34,239 | $5.1M | Aug 11, 2026 |
| PATEL DINESH V PH D | director officer | Buy | 65,761 | $1.4M | Aug 10, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-89.4%
3yr Revenue CAGR
20.1%
EPS Growth YoY
-148.46%
FCF Growth YoY
-69.3%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for PTGX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:36 | $134.38 | 1,749 | $$235K | SELL |
| 21:00:33 | $134.38 | 1,094 | $$147K | SELL |
| 21:00:33 | $134.38 | 2,857 | $$384K | SELL |
| 21:00:33 | $134.38 | 2,970 | $$399K | SELL |
| 21:00:33 | $134.38 | 2,128 | $$286K | SELL |
5 dark pool trades shown · $$1.5M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for PTGX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $140 | Dec 18 | 36 | $$2200 | 2 | SWEEP |
1 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for PTGX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $UBER — KHOSROWSHAHI DARA | Sale $10.0M $AOMR — MINAMI W D | Sale $55K $LITE — Wupen Yuen | Sale $481K $PTGX — PATEL DINESH V PH D | Sale $157K $PTGX — PATEL DINESH V PH D | Sale $1...
Join 3,500+ traders discussing PTGX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Protagonist Therapeutics, Inc (PTGX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Protagonist Therapeutics, Inc (PTGX) is at $134.38, down 0.36% (-$0.48) at the Nov 12, 2026 close.
Latest PTGX news — Nov 10, 2026: Wedbush Keeps Buy Rating on Protagonist Therapeutics · Nov 6, 2026: HC Wainwright keeps Buy rating on Protagonist Therapeutics, lifts target to $221
Protagonist Therapeutics shares closed at $144.88, down 0.65% on the day, despite two bullish analyst initiations. UBS initiated coverage with a Buy rating and a $184 price target, while Leerink Partners assumed coverage at Outperform and raised its price target to $190.
The average analyst price target for PTGX is $180.00, ranging from $116 to $221, based on 11 analysts. Latest: HC Wainwright & Co. maintains on Nov 6, 2026.
Analyst ratings for PTGX: 1 Buy, 16 Hold, 0 Sell — consensus Hold.
PTGX last reported on Nov 5, 2026: EPS $3.07 vs $2.50 expected — a beat of 22.8%.
PTGX trades at a P/E of 28.8 vs a Healthcare average of 17.1.
PTGX does not currently pay a dividend.
Support: $128.00, $103.71, $92.75. Resistance: $135.00, $146.44, $158.08.
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
Nov 10, 2026: Wedbush Keeps Buy Rating on Protagonist Therapeutics · Nov 6, 2026: HC Wainwright keeps Buy rating on Protagonist Therapeutics, lifts target to $221 · Nov 6, 2026: Analysts Raise Price Target on Protagonist Therapeutics (PTGX)